| Features: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| α-Santalol / Sandalwood oil — α-Santalol is a lipophilic sesquiterpene alcohol and major bioactive constituent of East Indian sandalwood oil from Santalum album. It is best classified as a natural-product small molecule / essential-oil sesquiterpenoid, with sandalwood oil functioning as a botanical mixture source rather than a single-compound drug. Standard abbreviations include α-SAN, alpha-santalol, and SAO or EISO for sandalwood album / East Indian sandalwood oil. The oncology evidence is primarily preclinical, strongest for skin, prostate, breast, and oral cancer models, with no established oncology indication. Primary mechanisms (ranked):
Bioavailability / PK relevance: α-Santalol is a small, highly lipophilic sesquiterpene alcohol, so topical and transdermal exposure is plausible, but formal human systemic PK data are limited. Oral/transdermal use should be treated as formulation- and dose-dependent, and essential-oil exposure is not equivalent to purified α-santalol exposure. In-vitro vs systemic exposure relevance: Most anticancer cell-culture studies use micromolar α-santalol concentrations, commonly around 20–75 μM depending on model and endpoint. These levels should be considered potentially above reliably documented human systemic exposure from sandalwood oil use, so in-vitro anticancer potency should not be interpreted as clinically achievable without dedicated PK/formulation data. Clinical evidence status: Preclinical for cancer prevention/therapy. Small human and dermatology-oriented evidence exists for sandalwood album oil in non-oncology skin conditions, and one clinical-trial context appears related to oral mucositis/supportive care rather than anticancer efficacy. No approved oncology indication and no high-quality human RCT evidence for cancer treatment were identified. α-Santalol and Sandalwood Oil Mechanistic Profile
P: 0–30 min R: 30 min–3 hr G: >3 hr |
| Source: |
| Type: |
| Biological process in which epithelial cells lose their cell polarity and cell-cell adhesion properties and gain mesenchymal traits, such as increased motility and invasiveness. This process is pivotal during embryogenesis and wound healing. Hh signaling pathway is able to regulate the EMT. Snail, E-cadherin and N-cadherin, key components of EMT; EMT-related factors, E-cadherin, N-cadherin, vimentin; The hallmark of EMT is the upregulation of N-cadherin followed by the downregulation of E-cadherin. EMT is regulated by various signaling pathways, including TGF-β, Wnt, Notch, and Hedgehog pathways. Transcription factors such as Snail, Slug, Twist, and ZEB play critical roles in repressing epithelial markers (like E-cadherin) and promoting mesenchymal markers (like N-cadherin and vimentin). EMT is associated with increased tumor aggressiveness, enhanced migratory and invasive capabilities, and resistance to apoptosis. |
| 6441- | SAO, | Sandalwood Album Oil as a Botanical Therapeutic in Dermatology |
| - | Review, | PSA, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:407 Target#:96 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid